These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 15868426)

  • 1. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
    Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI and conservative treatment of locally advanced breast cancer.
    Julius T; Kemp SE; Kneeshaw PJ; Chaturvedi A; Drew PJ; Turnbull LW
    Eur J Surg Oncol; 2005 Dec; 31(10):1129-34. PubMed ID: 15905068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study.
    Chou CP; Wu MT; Chang HT; Lo YS; Pan HB; Degani H; Furman-Haran E
    Acad Radiol; 2007 May; 14(5):561-73. PubMed ID: 17434070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
    Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy.
    Martincich L; Montemurro F; Cirillo S; Marra V; De Rosa G; Ponzone R; Aglietta M; Regge D
    Radiol Med; 2003; 106(1-2):51-8. PubMed ID: 12951551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
    Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
    Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI.
    Johansen R; Jensen LR; Rydland J; Goa PE; Kvistad KA; Bathen TF; Axelson DE; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2009 Jun; 29(6):1300-7. PubMed ID: 19472387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients.
    Nagashima T; Sakakibara M; Nakamura R; Arai M; Kadowaki M; Kazama T; Nakatani Y; Koda K; Miyazaki M
    Eur J Radiol; 2006 Nov; 60(2):270-4. PubMed ID: 16926079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI).
    Danishad KK; Sharma U; Sah RG; Seenu V; Parshad R; Jagannathan NR
    NMR Biomed; 2010 Apr; 23(3):233-41. PubMed ID: 20175134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Sharma U; Danishad KK; Seenu V; Jagannathan NR
    NMR Biomed; 2009 Jan; 22(1):104-13. PubMed ID: 18384182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
    Kang DK; Kim TH; Han TS; Kim KS; Yim H
    J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy.
    Yu HJ; Chen JH; Mehta RS; Nalcioglu O; Su MY
    J Magn Reson Imaging; 2007 Sep; 26(3):615-23. PubMed ID: 17729334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
    Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
    Wang XH; Peng WJ; Xin C; Tan HN; Gu YJ; Tang F; Mao J
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):539-43. PubMed ID: 21029700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
    Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
    Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
    Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study.
    Kumar M; Jagannathan NR; Seenu V; Dwivedi SN; Julka PK; Rath GK
    J Magn Reson Imaging; 2006 Aug; 24(2):325-32. PubMed ID: 16786567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic breast MRI in the course of neoadjuvant chemotherapy: standardized evaluation of tumor size and enhancement parameters in correlation to different histopathologic characteristics.
    Schlossbauer T; Sourbron S; Scholz A; Mosner M; Kahlert S; Böhm H; Reiser M; Hellerhoff K
    Acad Radiol; 2010 Apr; 17(4):441-9. PubMed ID: 20207315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.